Project Grant R01CA303068
Award Date
6/10/25
Completion Date
5/31/30
Dollars Obligated
$565K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $700,690 to Health Research, Inc. to decipher the molecular mechanisms underlying breast cancer bone metastasis. The research aims to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases, and how targeting YAP/TAZ could impede this cellular adaptation process. The long-term goals are to uncover the crosstalk...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the genomic and transcriptomic underpinnings of metastatic spread in triple-negative breast cancer (TNBC). The award period is from April 1, 2025 to March 31, 2030. The research will focus on decoding the co-evolution of cancer subclones and their tumor microenvironment across...
This federal Project Grant award for $719,799, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to investigate the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The award to Health Research, Inc. aims to determine how the metabolic enzyme PFKFB4 drives TNBC progression and metastasis through intrinsic regulation of metabolic and genetic pathways, as well...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), provides $645,323 to The Washington University to investigate the mechanisms by which breast cancer metastases to the bone impact immune function and resistance to immunotherapy. The research aims to understand how acidic signaling in the bone tumor microenvironment drives the evolution of immune-suppressive myeloid cells, which contribute to the lack of effectiveness of...
This federal Project Grant award of $542,663 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The University of Texas M.D. Anderson Cancer Center to investigate the role of BRG1/BRM-targeting ATPases in the treatment of acute myeloid leukemia (AML). The key objectives are to: 1) Determine the preclinical efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, and associated epigenomic and transcriptomic changes in...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $496,391 to the University of North Carolina at Chapel Hill to conduct research on manipulating lipid metabolism to reverse immune dysfunction in solid cancers. The research aims to understand how the tumor microenvironment impairs the metabolism of tumor-infiltrating lymphocytes (TILs), reducing their ability to effectively fight cancer. Specifically, the project will investigate how the...
This Project Grant award, titled "METABOLIC CONTROL OF MALIGNANT FATES IN LUNG CANCER", is funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396). The $730,400 award, with a period of performance from December 1, 2024 to November 30, 2029, will support research conducted by the Sloan-Kettering Institute for Cancer Research, a prominent non-profit cancer research organization in New York, NY. The research aims to determine how specific...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $179,988 to the University of Utah to conduct research on the role of dietary lipids in accelerating breast cancer tumor growth, particularly in the context of obesity. The key objectives are to: Determine if breast cancer cells preferentially utilize dietary lipids over glucose in lipid-rich environments, such as those found in obesity. Trace the metabolic fate of...
This federal Project Grant award, valued at $1,635,000.00 and funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the University of Texas MD Anderson Cancer Center to target a driver kinase, PCTK1, in combination with a ferroptosis inducer to combat breast cancer brain metastasis. The research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to...